Managing the Costs of GLP-1 Drugs: A Strategic Approach

June 2024
At Crystal Clear Rx (CCRx), we understand that the rising popularity and costs of GLP-1 drugs have raised many questions and concerns. We aim to provide clarity and guidance on managing these expenses effectively while ensuring patient care remains uncompromised.

Understanding GLP-1 Drugs
GLP-1 drugs are injectable medications prescribed for the treatment of diabetes and, increasingly, for weight loss. Their efficacy in promoting significant weight loss has made them popular among both patients and healthcare providers. However, this therapy comes with a substantial price tag—approximately $1,350 per month. Moreover, early studies suggest that discontinuation often leads to weight regain, indicating that these drugs may need to be taken indefinitely to maintain weight loss.

Side Effects and Patient Suitability
While effective, GLP-1 drugs are not without side effects. Common issues include gastrointestinal problems such as diarrhea, nausea, and abdominal pain. There are also potential serious side effects, and patients experiencing any adverse effects are strongly advised to consult their healthcare providers. Given these side effects, not all patients are suitable candidates for GLP-1 therapy. It is crucial for patients to have thorough discussions with their doctors to determine the best course of action.

CCRx’s Current Coverage Recommendations
Currently, CCRx advises our clients to cover GLP-1 drugs exclusively for diabetes treatment. Most Pharmacy Benefit Managers (PBMs) will require a diabetes diagnosis, and in some cases, additional documentation such as BMI data and other test results, before approving coverage.

Obesity and the Cost-Benefit Analysis
Obesity affects 60% of Americans and can lead to numerous severe and costly health issues. However, the high cost of GLP-1 therapy could potentially outweigh any savings derived from weight loss. Therefore, while we recognize the potential health benefits, the financial implications necessitate a cautious approach.

Looking Forward
CCRx is actively exploring solutions that could potentially alter the financial landscape of GLP-1 drugs. Until such solutions are viable, our stance remains to cover these medications solely for diabetes management. This strategy is expected to result in better patient health outcomes and reduced diabetes-related costs.

As GLP-1 drugs continue to gain popularity, CCRx anticipates that they will become the primary cost driver for many employer groups. We are committed to closely monitoring claims to ensure appropriate utilization and to support our clients in navigating these challenges.

We encourage you to reach out with any questions or concerns. Our team at Crystal Clear Rx is here to assist you in making informed decisions that balance cost management with patient care.

Recent Newsletters

What Is The Right Copay Strategy?

What Is The Right Copay Strategy? January 2024Crystal Clear Rx clients know that effectively managing the pharmacy benefit involves more than just PBM pricing. Utilization, Drug Mix, and Plan Design also impact the amount of money the Plan spends on their pharmacy...

The “Skinny” on Weight Loss Drugs

The “Skinny” on Weight Loss Drugs November 2023A lot of attention has been given lately to a new class of drugs called GLP-1’s. These drugs are increasingly being prescribed for type 2 diabetes and weight loss. Most Crystal Clear Rx clients cover these drugs for...

What to look for in a pharmacy benefit consultant

What to look for in a Pharmacy Benefit Consultant November 21, 2023Nobody wants to pay more than they should for any product or service. So, when many companies become concerned over pharmacy benefit costs, they may look for a Pharmacy Benefits Consultant or firm who...

Walgreens and CVS pharmacist Walk-outs

Walgreens and CVS pharmacist Walk-outs October 30th, 2023You may have recently seen news stories regarding pharmacist walk-outs at both Walgreens and CVS, and the potential for further work stoppages in the future at both of these companies, and potentially at other...

Choosing a PBM

Choosing a PBM September 2023 One of the primary services CCRx offers prospective clients is to assist them in the selection of a new pharmacy benefit manager, or PBM. Sometimes we are asked to utilize a Request for Proposal (RFP) process to narrow down the field of...

Effective Prior Authorization Management

Effective Prior Authorization Management August 2023 The effective management of the Prior Authorization (PA) function is a crucial aspect of healthcare that ensures patients receive the appropriate medications while controlling costs. Pharmacy Benefit Managers (PBMs)...

Conflict of Interest

Conflict of Interest July 2023 Recently a respected competitor published an article condemning most pharmacy benefit consultants for not disclosing conflicts of interest. They correctly pointed out that many big corporations such as “Boeing and UPS to local school...

New Transparency Models

New Transparency Models May 23, 2023 Both Express Scripts and OptumRx have announced new, optional Pass-Through pricing programs. Their clients can adopt this new pricing strategy, or they can continue with non-transparent pricing where the PBM won’t disclose the true...

Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company

Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company April 2023 The Mark Cuban Cost Plus Drug Company has announced that they have entered into a contract with JanssenUS, a subsidiary of Johnson and Johnson, to distribute Invokana, an important...